US6159460A
(en)
*
|
1988-05-27 |
2000-12-12 |
Amgen Inc. |
Method for treating interleukin-1 mediated diseases
|
US6858409B1
(en)
|
1988-05-27 |
2005-02-22 |
Amgen Inc. |
Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
|
US5075222A
(en)
|
1988-05-27 |
1991-12-24 |
Synergen, Inc. |
Interleukin-1 inhibitors
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
DK0393438T3
(da)
|
1989-04-21 |
2005-05-30 |
Amgen Inc |
TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
IL95031A
(en)
*
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
ATE190629T1
(de)
*
|
1991-01-18 |
2000-04-15 |
Amgen Inc |
Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
|
EP0708655A1
(en)
*
|
1993-04-07 |
1996-05-01 |
Amgen Boulder Inc. |
Methods of using insulin-like growth factor binding proteins
|
WO1995000162A1
(en)
*
|
1993-06-21 |
1995-01-05 |
Enzon, Inc. |
Site specific synthesis of conjugated peptides
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
CA2190752A1
(en)
*
|
1994-05-24 |
1995-11-30 |
George N. Cox |
Modified insulin-like growth factors
|
IT1269989B
(it)
*
|
1994-09-21 |
1997-04-16 |
Dompe Spa |
Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
|
AU3830895A
(en)
*
|
1994-10-07 |
1996-05-02 |
Amgen Boulder Inc. |
Dimeric il-4 inhibitors
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
FR2727117A1
(fr)
*
|
1994-11-18 |
1996-05-24 |
Geffard Michel |
Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
|
US5795966A
(en)
*
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
EP0867190B1
(en)
*
|
1995-05-10 |
2007-12-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cytotoxin complexes comprising dipeptides
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
CZ299025B6
(cs)
|
1996-02-09 |
2008-04-02 |
Amgen Inc. |
Farmaceutická kompozice a její použití
|
US5747639A
(en)
*
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
US5741778A
(en)
*
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
DE19636889A1
(de)
*
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
ES2312179T3
(es)
|
1996-12-06 |
2009-02-16 |
Amgen Inc. |
Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
|
JP2001513754A
(ja)
|
1996-12-06 |
2001-09-04 |
アムジェン インコーポレイテッド |
Tnf媒介疾患を処置するためのtnf結合タンパク質を使用する組み合わせ治療
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
IS4518A
(is)
*
|
1997-07-09 |
1999-01-10 |
Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group |
Nýtt lyfjaform fyrir bóluefni
|
US6013253A
(en)
*
|
1997-08-15 |
2000-01-11 |
Amgen, Inc. |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
|
AU9673998A
(en)
*
|
1997-10-01 |
1999-04-23 |
G.D. Searle & Co. |
Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
|
CA2310575A1
(en)
*
|
1997-11-07 |
1999-05-20 |
Uab Research Foundation |
Method for the augmentation of gene expression
|
US6451986B1
(en)
*
|
1998-06-22 |
2002-09-17 |
Immunex Corporation |
Site specific protein modification
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
CN1896231B
(zh)
|
1998-08-06 |
2012-09-05 |
山景药品公司 |
分离四聚体尿酸氧化酶的方法
|
CN101062419B
(zh)
|
1998-10-16 |
2016-06-29 |
生物基因Ma公司 |
干扰素-β-1a的聚合物缀合物及其使用
|
WO2000023472A2
(en)
|
1998-10-16 |
2000-04-27 |
Biogen, Inc. |
Interferon-beta fusion proteins and uses
|
DE122009000039I1
(de)
|
1998-10-23 |
2009-11-05 |
Kirin Amgen Inc |
Thrombopoietin substitute
|
CA2369869C
(en)
|
1999-04-02 |
2008-06-10 |
Ajinomoto Co., Inc. |
Process for producing subunit peptide originating in polymer protein
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US8106098B2
(en)
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US6602498B2
(en)
|
2000-02-22 |
2003-08-05 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
AU2001259758A1
(en)
|
2000-05-12 |
2001-11-26 |
Immunex Corporation |
Interleukin-1 inhibitors in the treatment of diseases
|
US7387993B2
(en)
*
|
2000-07-13 |
2008-06-17 |
Natimmune A/S |
Mannan-binding lectin (MBL) treatment of infections in individuals treated with TNF-αinhibitors
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
SG10201603108QA
(en)
|
2001-06-26 |
2016-05-30 |
Amgen Inc |
Antibodies To OPGL
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
JP4123856B2
(ja)
*
|
2001-07-31 |
2008-07-23 |
日油株式会社 |
生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
|
GB0125093D0
(en)
*
|
2001-10-18 |
2001-12-12 |
Univ Southampton |
Multimeric proteins
|
DK1562968T3
(da)
|
2001-11-14 |
2013-10-28 |
Janssen Biotech Inc |
Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
US20030149246A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Russell John C. |
Macromolecular conjugates and processes for preparing the same
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
US20040002451A1
(en)
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
JP2006504406A
(ja)
|
2002-06-28 |
2006-02-09 |
セントカー・インコーポレーテツド |
哺乳動物のch1欠失ミメティボディ、組成物、方法および使用
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
NZ538569A
(en)
|
2002-09-06 |
2009-02-28 |
Amgen Inc |
Therapeutic human anti-IL-1R1 monoclonal antibody
|
JP2005539067A
(ja)
*
|
2002-09-16 |
2005-12-22 |
エリューシス セラピューティクス,インコーポレーテッド |
ポリエチレングリコールリンカーを用いる二重特異性分子の産生
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7432331B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
EP1578841B2
(en)
|
2002-12-31 |
2016-10-12 |
Nektar Therapeutics AL, Corporation |
Maleamic acid polymer derivatives and their bioconjugates
|
KR101025143B1
(ko)
|
2002-12-31 |
2011-04-01 |
넥타르 테라퓨틱스 |
가수분해상으로 안정한 말레이미드-종결 중합체
|
US20050176108A1
(en)
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
EP1625156B1
(en)
|
2003-05-12 |
2012-09-19 |
Affymax, Inc. |
Peptides that bind to the erythropoietin receptor
|
AU2004238364A1
(en)
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Spacer moiety for poly(ethylene glycol) -modified peptides
|
KR101163683B1
(ko)
|
2003-05-12 |
2012-07-10 |
아피맥스, 인크. |
에리스로포이에틴 수용체에 결합하는 신규의 펩티드
|
CA2525464A1
(en)
*
|
2003-05-12 |
2004-11-25 |
Qun Yin |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
EP1491554A1
(en)
*
|
2003-06-23 |
2004-12-29 |
CONARIS research institute AG |
PEGylated soluble gp130-dimers useful as a medicament
|
US7482376B2
(en)
*
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
GB0316294D0
(en)
|
2003-07-11 |
2003-08-13 |
Polytherics Ltd |
Conjugated biological molecules and their preparation
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
CA2543484C
(en)
|
2003-10-27 |
2014-02-04 |
Amgen Inc. |
Modulation of immune response to an immunogen with ctla-4 and tnfbp
|
PT2239273E
(pt)
|
2003-11-13 |
2013-12-10 |
Hanmi Science Co Ltd |
Uma composição farmacêutica que compreende um fragmento fc de imunoglobulina como um portador
|
WO2005056636A2
(en)
|
2003-12-03 |
2005-06-23 |
Nektar Therapeutics Al, Corporation |
Method of preparing maleimide functionalized polymers
|
IL159670A0
(en)
*
|
2003-12-31 |
2004-06-01 |
Yeda Res & Dev |
Use of il-18 binding protein in inflammations
|
US7674464B2
(en)
*
|
2004-03-04 |
2010-03-09 |
The University Of Tennessee Research Foundation |
Intracellular interleukin-1 receptor antagonists
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
CA2572765C
(en)
|
2004-07-08 |
2013-05-21 |
Amgen Inc. |
Compound having improved bioefficiency when administered in a multidose regimen
|
CA2574654C
(en)
|
2004-07-22 |
2014-02-18 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
AU2005296277A1
(en)
*
|
2004-10-12 |
2006-04-27 |
Amprotein Corporation |
Chimeric protein
|
EP2236153A3
(en)
|
2005-01-25 |
2012-08-22 |
Five Prime Therapeutics, Inc. |
Compositons and methods for treating cardiac conditions
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
CN100381420C
(zh)
*
|
2005-03-23 |
2008-04-16 |
于勇海 |
一种n-乙酰基半胱氨酸衍生物与应用
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
JP2008535500A
(ja)
|
2005-04-11 |
2008-09-04 |
サビエント ファーマセウティカルズ インク. |
変異型尿酸オキシダーゼおよびその利用
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
CN102961746B
(zh)
|
2005-05-16 |
2016-06-15 |
艾伯维生物技术有限公司 |
TNFα抑制剂治疗腐蚀性多关节炎的用途
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
PL2452694T3
(pl)
|
2005-06-30 |
2019-06-28 |
Janssen Biotech, Inc |
Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
EP3219328B1
(en)
|
2005-12-29 |
2020-06-17 |
Janssen Biotech, Inc. |
Human anti-il-23 antibodies, compositions, method and uses
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
WO2007095660A1
(en)
|
2006-02-23 |
2007-08-30 |
Fibrex Medical Research & Development Gmbh |
Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
|
DK2004683T3
(en)
|
2006-03-24 |
2016-08-22 |
Biogen Hemophilia Inc |
PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
|
NZ596517A
(en)
|
2006-04-05 |
2013-06-28 |
Abbott Biotech Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
EP2061489A4
(en)
*
|
2006-09-15 |
2009-12-23 |
Burnham Inst |
COMPOUNDS BINDING EPHB RECEPTORS WITH HIGH AFFINITY AND METHODS OF USE THEREOF
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
AR063384A1
(es)
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
EA019661B1
(ru)
|
2006-12-08 |
2014-05-30 |
Лексикон Фармасьютикалз, Инк. |
Моноклональные антитела против angptl3
|
UY30820A1
(es)
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
WO2008116347A1
(en)
|
2007-03-26 |
2008-10-02 |
General Regeneratives Limited |
Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
|
GB0708376D0
(en)
|
2007-05-01 |
2007-06-06 |
Alligator Bioscience Ab |
Novel polypeptides and uses thereof
|
EP2738257A1
(en)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
EA201070231A1
(ru)
|
2007-08-09 |
2010-10-29 |
Синтоникс Фармасьютикалз, Инк. |
Иммуномодулирующие пептиды
|
US8323635B2
(en)
|
2007-11-14 |
2012-12-04 |
General Regeneratives, Ltd. |
Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
|
NZ590358A
(en)
|
2008-07-23 |
2012-04-27 |
Hanmi Holdings Co Ltd |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
US8088890B2
(en)
|
2008-09-26 |
2012-01-03 |
Fibrex Medical Research & Development Gmbh |
Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
|
CA2741834C
(en)
|
2008-10-31 |
2022-04-05 |
Centocor Ortho Biotech Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
MX2011004718A
(es)
*
|
2008-11-04 |
2011-07-28 |
Janssen Pharmaceutica Nv |
Péptidos agonistas de crhr2 y usos de éstos.
|
GB0823309D0
(en)
*
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
US8536375B2
(en)
|
2008-12-22 |
2013-09-17 |
Ge Healthcare Limited |
Synthesis of obtaining modified polyethylene glycol intermediates
|
MX2011008566A
(es)
|
2009-02-12 |
2011-11-29 |
Janssen Biotech Inc |
Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos.
|
SG176897A1
(en)
|
2009-06-25 |
2012-01-30 |
Savient Pharmaceuticals Inc |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
CA2772051C
(en)
|
2009-08-24 |
2020-08-18 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
CN101690801B
(zh)
|
2009-10-26 |
2012-08-01 |
上海交通大学 |
白细胞介素-1受体拮抗剂的用途及其药物组合物
|
EA031209B9
(ru)
|
2010-01-15 |
2021-11-19 |
Кирин-Эмджен, Инк. |
Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
|
MX2012011479A
(es)
|
2010-03-30 |
2012-12-17 |
Janssen Biotech Inc |
Anticuerpos de interleucina-25 humanizados.
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
AU2011268110B2
(en)
|
2010-06-19 |
2016-05-19 |
Memorial Sloan-Kettering Cancer Center |
Anti-GD2 antibodies
|
US8431532B2
(en)
|
2010-06-28 |
2013-04-30 |
Five Prime Therepeutics, Inc. |
FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
|
EP3508573A1
(en)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
EA025828B1
(ru)
|
2010-11-15 |
2017-02-28 |
Файв Прайм Терапьютикс, Инк. |
Комбинированная терапия внеклеточным доменом fgfr1
|
CN103298490B
(zh)
|
2010-11-24 |
2017-04-26 |
莱克康制药公司 |
结合背板胶质乙酰酯酶的抗体
|
WO2012097238A2
(en)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Il-27 antagonists for treating inflammatory diseases
|
SG193434A1
(en)
|
2011-03-16 |
2013-10-30 |
Amgen Inc |
Potent and selective inhibitors of nav1.3 and nav1.7
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
TWI687226B
(zh)
|
2011-07-08 |
2020-03-11 |
美商百歐維拉提夫治療公司 |
因子viii嵌合及雜交多肽,及其使用方法
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
IL230564B2
(en)
|
2011-07-22 |
2023-09-01 |
Csl Ltd |
Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
|
EA029602B1
(ru)
|
2011-11-29 |
2018-04-30 |
Проклара Байосайенсиз, Инк. |
Применение белков р3 бактериофага в качестве агентов, связывающих амилоид
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
EA201491470A1
(ru)
|
2012-02-15 |
2015-01-30 |
Амуникс Оперэйтинг Инк. |
Композиции фактора viii и способы получения и использования подобных
|
KR20190094480A
(ko)
|
2012-02-15 |
2019-08-13 |
바이오버라티브 테라퓨틱스 인크. |
재조합 인자 viii 단백질
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
CA2872908C
(en)
|
2012-05-10 |
2023-11-14 |
Gerhard Frey |
Multi-specific monoclonal antibodies
|
DK2849567T3
(da)
|
2012-05-17 |
2022-06-20 |
Extend Biosciences Inc |
Bærestoffer til forbedret lægemiddeladministration
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
PT2906235T
(pt)
|
2012-10-02 |
2017-09-28 |
Proclara Biosciences Inc |
Utilização de p3 de proteínas de fusão de bacteriófago como agentes ligantes amilóides
|
WO2014063108A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
EP3446700A1
(en)
|
2012-10-30 |
2019-02-27 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
KR102403299B1
(ko)
|
2013-03-08 |
2022-06-03 |
체에스엘 베링 게엠베하 |
원격 허혈-재관류 손상의 치료 및 예방
|
WO2014165277A2
(en)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
POTENT AND SELECTIVE INHIBITORS OF Nav1.7
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US10588949B2
(en)
|
2013-03-15 |
2020-03-17 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
WO2014144763A2
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-gd2 antibodies
|
EP4122487A1
(en)
|
2013-03-15 |
2023-01-25 |
Bioverativ Therapeutics Inc. |
Factor viii polypeptide formulations
|
CA2908391A1
(en)
|
2013-05-01 |
2014-11-06 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
WO2014190147A2
(en)
|
2013-05-23 |
2014-11-27 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
KR20160010618A
(ko)
|
2013-05-28 |
2016-01-27 |
뉴로페이지 파마슈티컬즈, 인크. |
감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
|
CA2916399C
(en)
|
2013-06-28 |
2022-08-02 |
Marc Nolte |
Combination therapy using a factor xii inhibitor and a c1-inhibitor
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
EP4108254A1
(en)
|
2013-08-14 |
2022-12-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20160296600A1
(en)
|
2013-11-11 |
2016-10-13 |
Ascendis Pharma Relaxin Division A/S |
Relaxin Prodrugs
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
ES2967617T3
(es)
|
2013-12-06 |
2024-05-03 |
Bioverativ Therapeutics Inc |
Herramientas de farmacocinética poblacional y sus usos
|
TWI700101B
(zh)
|
2014-03-24 |
2020-08-01 |
美商百歐維拉提夫治療公司 |
凍乾之因子ix調配物
|
US20170174772A1
(en)
|
2014-03-31 |
2017-06-22 |
Kirin-Amgen, Inc. |
Methods of treating nail and scalp psoriasis
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
CA2951391C
(en)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Apelin polypeptides
|
US20160000936A1
(en)
|
2014-06-10 |
2016-01-07 |
Abbvie Inc. |
Biomarkers for inflammatory disease and methods of using same
|
PL3157548T3
(pl)
|
2014-06-18 |
2022-01-17 |
Csl Behring Gmbh |
Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
|
WO2016053882A2
(en)
|
2014-09-29 |
2016-04-07 |
Fred Hutchinson Cancer Research Center |
Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
|
EP3220961B1
(en)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
KR20170085132A
(ko)
|
2014-12-03 |
2017-07-21 |
프로클라라 바이오사이언시즈, 인크. |
글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드
|
ES2929614T3
(es)
|
2015-03-17 |
2022-11-30 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-MUC16 y usos de los mismos
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
CA3019164A1
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
MA45473A
(fr)
|
2016-04-04 |
2019-02-13 |
Shire Human Genetic Therapies |
Inhibiteur de c1 estérase conjugué et ses utilisations
|
WO2017173494A1
(en)
|
2016-04-06 |
2017-10-12 |
Csl Limited |
Method of treating atherosclerosis
|
CN109414481B
(zh)
|
2016-04-25 |
2022-11-01 |
葛兰素史克知识产权开发有限公司 |
用于治疗病理性肌肉损失和虚弱的nope
|
TWI759301B
(zh)
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
AU2017297603A1
(en)
|
2016-07-14 |
2019-02-14 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
WO2018014039A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
EP3484914A1
(en)
|
2016-07-15 |
2019-05-22 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
WO2018022982A1
(en)
|
2016-07-29 |
2018-02-01 |
Trustees Of Boston University |
Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
|
AU2017336799B2
(en)
|
2016-09-30 |
2023-08-31 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL23 specific antibody
|
EP3541422A4
(en)
|
2016-11-16 |
2020-05-06 |
Janssen Biotech, Inc. |
METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
MX2019006446A
(es)
|
2016-12-02 |
2019-12-11 |
Bioverativ Therapeutics Inc |
Métodos para inducir tolerancia inmunológica a factores de coagulación.
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
CN110831613A
(zh)
|
2017-01-31 |
2020-02-21 |
比奥维拉迪维治疗股份有限公司 |
因子ix融合蛋白及其制备和使用方法
|
CA3052578A1
(en)
|
2017-02-07 |
2018-08-16 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
CA3056227A1
(en)
|
2017-03-13 |
2018-09-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018209125A1
(en)
|
2017-05-10 |
2018-11-15 |
Fred Hutchinson Cancer Research Center |
Epstein barr virus antibodies, vaccines, and uses of the same
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
AU2018393110B2
(en)
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
MX2020009265A
(es)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
|
CA3092947A1
(en)
|
2018-03-07 |
2019-09-12 |
Poseida Therapeutics, Inc. |
Cartyrin compositions and methods for use
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
AU2019268410A1
(en)
|
2018-05-16 |
2020-12-17 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
AU2019270184A1
(en)
|
2018-05-18 |
2020-11-26 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia A
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
JP7359845B2
(ja)
|
2018-09-24 |
2023-10-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
|
EP3883607A4
(en)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
CA3124103A1
(en)
|
2018-12-20 |
2020-06-25 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
JP2022518250A
(ja)
|
2019-01-23 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
乾癬性関節炎の治療方法で使用するための抗tnf抗体組成物
|
JP2022525179A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための産生方法
|
WO2020183271A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
US20200291107A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
WO2020188466A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
US20220323580A1
(en)
|
2019-06-03 |
2022-10-13 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
CN114173873A
(zh)
|
2019-06-03 |
2022-03-11 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CA3149892A1
(en)
|
2019-09-05 |
2021-03-11 |
Eric M. Ostertag |
Allogeneic cell compositions and methods of use
|
EP4077395A1
(en)
|
2019-12-20 |
2022-10-26 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
EP4118107A1
(en)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
US20230190811A1
(en)
|
2020-04-14 |
2023-06-22 |
Poseida Therapeutics, Inc. |
Compositions and methods for use in the treatment of cancer
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
EP4231999A1
(en)
|
2020-10-21 |
2023-08-30 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
MX2023009850A
(es)
|
2021-02-23 |
2023-08-29 |
Poseida Therapeutics Inc |
Composiciones y metodos para la administracion de acidos nucleicos.
|
WO2022182797A1
(en)
|
2021-02-23 |
2022-09-01 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
US20230038355A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20240032991A
(ko)
|
2021-07-09 |
2024-03-12 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 생성을 위한 제조 방법
|
EP4413141A1
(en)
|
2021-10-04 |
2024-08-14 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
KR20240107176A
(ko)
|
2021-11-15 |
2024-07-08 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
KR20240103043A
(ko)
|
2021-11-23 |
2024-07-03 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|